KR20210110645A - 갈렉틴-3 억제 c-글리코사이드 - Google Patents
갈렉틴-3 억제 c-글리코사이드 Download PDFInfo
- Publication number
- KR20210110645A KR20210110645A KR1020217023786A KR20217023786A KR20210110645A KR 20210110645 A KR20210110645 A KR 20210110645A KR 1020217023786 A KR1020217023786 A KR 1020217023786A KR 20217023786 A KR20217023786 A KR 20217023786A KR 20210110645 A KR20210110645 A KR 20210110645A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- groups
- subject
- administering
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- NUIRXVBKWCLTQE-UWXRGJDJSA-N CC(C1O)C2OC(c3ccccc3)OCC2O[C@H]1Sc1ccccc1 Chemical compound CC(C1O)C2OC(c3ccccc3)OCC2O[C@H]1Sc1ccccc1 NUIRXVBKWCLTQE-UWXRGJDJSA-N 0.000 description 1
- CBFQSUSAVYJIDO-BJFJLSACSA-N CC(C1[n]2nnc(-c(cc3F)cc(F)c3F)c2)[C@]2(O[C@@H]2C(OC)=O)OC(COCc2ccccc2)[C@@H]1OCc1ccccc1 Chemical compound CC(C1[n]2nnc(-c(cc3F)cc(F)c3F)c2)[C@]2(O[C@@H]2C(OC)=O)OC(COCc2ccccc2)[C@@H]1OCc1ccccc1 CBFQSUSAVYJIDO-BJFJLSACSA-N 0.000 description 1
- 0 CC(OCC(C(C(*)C1OC(C)=O)OC(C)=O)O[C@]1Sc1ccccc1)=O Chemical compound CC(OCC(C(C(*)C1OC(C)=O)OC(C)=O)O[C@]1Sc1ccccc1)=O 0.000 description 1
- XVCKBGQNVPEPSL-PSVAPKRXSA-N CC([C@H](C(CO)OC1Sc2ccccc2)O)C1OC Chemical compound CC([C@H](C(CO)OC1Sc2ccccc2)O)C1OC XVCKBGQNVPEPSL-PSVAPKRXSA-N 0.000 description 1
- SPAJGVGYAUVDFM-IYXWTRKOSA-N CNC([C@H]([C@@H](C(C1[n]2nnc(-c(cc3F)cc(F)c3F)c2)O)OC(CO)C1O)OCc1cccc(Cl)c1)=O Chemical compound CNC([C@H]([C@@H](C(C1[n]2nnc(-c(cc3F)cc(F)c3F)c2)O)OC(CO)C1O)OCc1cccc(Cl)c1)=O SPAJGVGYAUVDFM-IYXWTRKOSA-N 0.000 description 1
- HWENPQLJDBSORL-RLVOOELNSA-N CNC([C@H]([C@@H](C(C1[n]2nnc(-c(cc3F)cc(F)c3F)c2)O)OC(CO)[C@@H]1O)OCc1cccc(C(OC)=O)c1)=O Chemical compound CNC([C@H]([C@@H](C(C1[n]2nnc(-c(cc3F)cc(F)c3F)c2)O)OC(CO)[C@@H]1O)OCc1cccc(C(OC)=O)c1)=O HWENPQLJDBSORL-RLVOOELNSA-N 0.000 description 1
- DQZJDMMIQUOGGL-QMCMHKDVSA-N COC([C@H]([C@@H](C(C1[n]2nnc(-c(cc3F)cc(F)c3F)c2)O)OC2[C@@H]1OC(c1ccccc1)OC2)O)=O Chemical compound COC([C@H]([C@@H](C(C1[n]2nnc(-c(cc3F)cc(F)c3F)c2)O)OC2[C@@H]1OC(c1ccccc1)OC2)O)=O DQZJDMMIQUOGGL-QMCMHKDVSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/08—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to sulfur, selenium or tellurium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862785588P | 2018-12-27 | 2018-12-27 | |
| US62/785,588 | 2018-12-27 | ||
| US201962927192P | 2019-10-29 | 2019-10-29 | |
| US62/927,192 | 2019-10-29 | ||
| PCT/US2019/068597 WO2020139960A1 (en) | 2018-12-27 | 2019-12-26 | Galectin-3 inhibiting c-glycosides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20210110645A true KR20210110645A (ko) | 2021-09-08 |
Family
ID=69191291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217023786A Ceased KR20210110645A (ko) | 2018-12-27 | 2019-12-26 | 갈렉틴-3 억제 c-글리코사이드 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11873317B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3902797A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7547345B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210110645A (cg-RX-API-DMAC7.html) |
| CN (2) | CN113490665B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019416330A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021012482A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3122321A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020139960A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7547345B2 (ja) | 2018-12-27 | 2024-09-09 | グリコミメティクス, インコーポレイテッド | ガレクチン-3阻害性c-グリコシド |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| CN115244045A (zh) * | 2019-12-24 | 2022-10-25 | 糖模拟物有限公司 | 抑制半乳凝素-3的c-糖苷酮、醚和醇 |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| WO2022073969A1 (en) * | 2020-10-06 | 2022-04-14 | Idorsia Pharmaceuticals Ltd | Spiro derivatives of alpha-d-galactopyranosides |
| US12291520B2 (en) * | 2020-11-02 | 2025-05-06 | Idorsia Pharmaceuticals Ltd | Galectin-3 inhibiting 2-hydroxycycloalkane-1-carbamoyl derivatives |
| WO2022241183A1 (en) | 2021-05-14 | 2022-11-17 | Glycomimetics, Inc. | Galectin-3 inhibiting c-glycosides |
| WO2022250976A1 (en) * | 2021-05-28 | 2022-12-01 | Glycomimetics, Inc. | Galectin-3 inhibiting c-glycoside oximes |
| WO2024220435A1 (en) * | 2023-04-18 | 2024-10-24 | Truebinding, Inc. | Methods of treating eye disease |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK455088D0 (da) | 1988-08-12 | 1988-08-12 | Symbicom Ab | Syntetiske receptoranaloger |
| CA2106301C (en) | 1991-03-18 | 1999-04-06 | Chi-Huey Wong | Oligosaccharide enzyme substrates and inhibitors: method and compositions |
| US5620864A (en) | 1992-06-29 | 1997-04-15 | Health Research, Inc. | Acceptor for fucosyl transferase |
| DK76193D0 (da) | 1993-06-25 | 1993-06-25 | Astra Ab | Kulhydratderivater |
| DE19643764A1 (de) | 1996-09-30 | 1998-04-02 | Bayer Ag | Glycokonjugate von modifizierten Camptothecin-Derivaten (20-0-Verknüpfung) |
| DE19654180A1 (de) | 1996-12-23 | 1998-06-25 | Hoechst Ag | Phosphane, Verfahren zu ihrer Herstellung und ihre Verwendung in Metallkomplexen |
| US6323176B1 (en) | 1998-02-25 | 2001-11-27 | Eli Lilly And Company | Cyclic peptide antifungal agents |
| WO2000035945A1 (en) | 1998-12-16 | 2000-06-22 | Eli Lilly And Company | Cyclic peptide antifungal agents having a sugar substituent |
| SE0100172D0 (sv) | 2001-01-22 | 2001-01-22 | Ulf Nilsson | New inhibitors against galectins |
| FR2835527B1 (fr) | 2002-02-05 | 2004-03-12 | Centre Nat Rech Scient | Synthese de molecules de type inositolphosphate glycanne: traitement des troubles de la proliferation cellulaire et des desordres metaboliques caracterises par une resistance a l'insuline |
| AUPS213802A0 (en) | 2002-05-03 | 2002-06-06 | Alchemia Pty Ltd | Disaccharides for drug discovery |
| CA2528152A1 (en) | 2003-06-03 | 2005-01-06 | The Regents Of The University Of California | Compositions and methods for treatment of disease with acetylated disaccharides |
| WO2005061523A1 (en) | 2003-12-23 | 2005-07-07 | Progen Industries Limited | Glycosaminoglycan (gag) mimetics |
| SE0401300D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| SE0401301D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors of galectins |
| EP1632498A1 (en) | 2004-09-03 | 2006-03-08 | Syngenta Participations AG | Derivatives of avermectin, avermectin monosaccharide and avermectin aglycone |
| WO2007021721A2 (en) | 2005-08-09 | 2007-02-22 | Glycomimetics, Inc. | Glycomimetic inhibitors of the pa-il lectin, pa-iil lectin or both the lectins from pseudomonas |
| US20090214439A1 (en) | 2006-03-15 | 2009-08-27 | Trustees Of Tufts College | Fluorinated Carbohydrates and Their Use in Tumor Visualization, Tissue Engineering, and Cancer Chemotherapy |
| US20090176717A1 (en) | 2006-06-01 | 2009-07-09 | Glycomimetics, Inc. | Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas |
| GB0614947D0 (en) | 2006-07-27 | 2006-09-06 | Isis Innovation | Epitope reduction therapy |
| EP1964846A1 (en) | 2007-02-27 | 2008-09-03 | Bracco Imaging, S.P.A. | Process for the preparation of contrast agents |
| GB0712494D0 (en) | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
| KR102085687B1 (ko) | 2008-04-08 | 2020-03-06 | 슬로안-케테링인스티튜트퍼캔서리서치 | 트리테르펜 사포닌, 그의 합성 방법, 및 그의 용도 |
| US8697862B2 (en) | 2008-05-16 | 2014-04-15 | Galecto Biotech Ab | Synthesis of galactoside inhibitors |
| US9220767B2 (en) | 2008-10-08 | 2015-12-29 | Abivax | Vaccine composition for use against influenza |
| ES2652488T3 (es) | 2009-04-28 | 2018-02-02 | Galecto Biotech Ab | Nuevos inhibidores de galactósidos de galectinas |
| WO2011002673A1 (en) | 2009-07-01 | 2011-01-06 | Temple University - Of The Commonwealth System Of Higher Education | Leptin agonist and methods of use |
| US9624255B2 (en) | 2009-08-11 | 2017-04-18 | Arizona Board Of Regents | Carbohydrate-mediated tumor targeting |
| WO2011129314A1 (ja) | 2010-04-13 | 2011-10-20 | 和光純薬工業株式会社 | 糖類の重水素化方法 |
| US9243021B2 (en) | 2012-10-31 | 2016-01-26 | Galecto Biotech Ab | Galactoside inhibitor of galectins |
| EP2620443A1 (en) | 2012-01-25 | 2013-07-31 | Galecto Biotech AB | Novel galactoside inhibitors of galectins |
| WO2013170985A1 (en) | 2012-05-18 | 2013-11-21 | Boettger Erik C | New aminoglycoside antibiotics targeting bacterial 16s ribosomal rna lacking ototoxicity |
| EP2859112A4 (en) | 2012-06-08 | 2015-10-28 | Glycom As | PROCESS FOR THE PREPARATION OF OLIGOSACCHARIDES AND OLIGOSACCHARIDE GLYCOSIDES BY FERMENTATION |
| GB201214736D0 (en) | 2012-08-17 | 2012-10-03 | Isis Innovation | Inflammation imaging and therapy |
| HRP20180268T4 (hr) | 2012-10-23 | 2026-03-27 | Synaffix B.V. | Modificirano antitijelo, konjugat antitijela i postupak za njihovu pripremu |
| IN2015DN02573A (cg-RX-API-DMAC7.html) | 2012-10-31 | 2015-09-11 | Galecto Biotech Ab | |
| EP2919802A4 (en) | 2012-11-15 | 2016-09-14 | Univ Tufts | METHOD, COMPOSITIONS AND KITS FOR TREATING, MODULATING OR PREVENTING ANGIOGENESIS OR FIBROSIS IN A PATIENT USING A GALECTINE PROTEIN HEMMER |
| GB2511137A (en) | 2013-02-26 | 2014-08-27 | Glykos Finland Oy | Chelator Molecule |
| AU2014236356A1 (en) | 2013-03-14 | 2015-09-24 | The Regents Of The University Of California | Thiosaccharide mucolytic agents |
| DK2991683T3 (da) | 2013-05-02 | 2019-11-04 | Glykos Finland Oy | Konjugater af et glykoprotein eller en glykan med en toksisk ladning |
| US20170095496A1 (en) | 2014-04-08 | 2017-04-06 | Galecto Biotech Ab | Galactoside inhibitors for new uses |
| FR3020952B1 (fr) | 2014-05-14 | 2017-09-08 | Adocia | Formulation a action rapide d'insuline comprenant un compose anionique substitue et un compose polyanionique |
| WO2015197082A1 (en) | 2014-06-27 | 2015-12-30 | Glycom A/S | Oligosaccharide production |
| JP6735680B2 (ja) | 2014-07-09 | 2020-08-05 | ガレクト バイオテック エービー | ガレクチンの新規ハイブリッドガラクトシド阻害剤 |
| US20170274087A1 (en) | 2014-09-19 | 2017-09-28 | Emory University | Saccharide analogs and agents for the diagnosis and therapy of bacterial infections |
| WO2016113335A1 (en) | 2015-01-16 | 2016-07-21 | Galecto Biotech Ab | Novel galactoside inhibitor of galectins |
| CA2970062C (en) * | 2015-01-30 | 2023-02-28 | Galecto Biotech Ab | Alpha-d-galactoside inhibitors of galectins |
| US11406655B2 (en) | 2015-05-12 | 2022-08-09 | Galecto Biotech Ab | Once-daily treatment of pulmonary fibrosis |
| US10799522B2 (en) | 2015-07-27 | 2020-10-13 | Wayne State University | Compositions and methods relating to galectin detection |
| CA3000924A1 (en) | 2015-11-09 | 2017-05-18 | Galecto Biotech Ab | Novel galactoside inhibitors of galectins |
| CN109563119A (zh) * | 2016-07-12 | 2019-04-02 | 格莱克特生物技术公司 | 半乳糖凝集素的α-D-半乳糖苷抑制剂 |
| KR102626669B1 (ko) | 2017-05-12 | 2024-01-17 | 갈랙틴 사이언시즈, 엘엘씨 | 질환의 예방 및 치료를 위한 화합물 및 이의 용도 |
| CA3062649A1 (en) | 2017-05-12 | 2018-11-15 | Galectin Sciences, Llc | Compounds for the treatment of systemic insulin resistance disorders and the use thereof |
| US11267811B2 (en) | 2017-09-27 | 2022-03-08 | Bristol-Myers Squibb Company | Small molecule inhibitors of galectin-3 |
| WO2019075045A1 (en) | 2017-10-11 | 2019-04-18 | Bristol-Myers Squibb Company | INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3 |
| US11548908B2 (en) | 2017-12-29 | 2023-01-10 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
| JP7547345B2 (ja) | 2018-12-27 | 2024-09-09 | グリコミメティクス, インコーポレイテッド | ガレクチン-3阻害性c-グリコシド |
| US11845771B2 (en) | 2018-12-27 | 2023-12-19 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
| CA3136661A1 (en) | 2019-04-24 | 2020-10-29 | Glycomimetics, Inc. | Galactose-linked multimeric glycomimetic inhibitors of e-selectins, galectin-3, and/or cxcr4 chemokine receptors |
| WO2021086816A1 (en) | 2019-10-29 | 2021-05-06 | Glycomimetics, Inc. | Galectin-3 inhibiting c-glycosides |
-
2019
- 2019-12-26 JP JP2021537087A patent/JP7547345B2/ja active Active
- 2019-12-26 AU AU2019416330A patent/AU2019416330A1/en not_active Abandoned
- 2019-12-26 CA CA3122321A patent/CA3122321A1/en active Pending
- 2019-12-26 CN CN201980086267.8A patent/CN113490665B/zh not_active Expired - Fee Related
- 2019-12-26 BR BR112021012482-9A patent/BR112021012482A2/pt not_active IP Right Cessation
- 2019-12-26 WO PCT/US2019/068597 patent/WO2020139960A1/en not_active Ceased
- 2019-12-26 US US17/418,590 patent/US11873317B2/en active Active
- 2019-12-26 CN CN202410463772.2A patent/CN118373810A/zh active Pending
- 2019-12-26 KR KR1020217023786A patent/KR20210110645A/ko not_active Ceased
- 2019-12-26 EP EP19842722.1A patent/EP3902797A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN113490665A (zh) | 2021-10-08 |
| EP3902797A1 (en) | 2021-11-03 |
| US11873317B2 (en) | 2024-01-16 |
| WO2020139960A1 (en) | 2020-07-02 |
| CA3122321A1 (en) | 2020-07-02 |
| AU2019416330A1 (en) | 2021-07-01 |
| JP7547345B2 (ja) | 2024-09-09 |
| CN118373810A (zh) | 2024-07-23 |
| BR112021012482A2 (pt) | 2021-09-08 |
| JP2022516075A (ja) | 2022-02-24 |
| CN113490665B (zh) | 2024-05-07 |
| US20220073555A1 (en) | 2022-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7547345B2 (ja) | ガレクチン-3阻害性c-グリコシド | |
| JP7304863B2 (ja) | E-セレクチンおよびガレクチン-3のヘテロ二機能性阻害剤 | |
| US20240150388A1 (en) | Heterobifunctional inhibitors of e-selectin and galectin-3 | |
| KR20190062509A (ko) | 매우 강력한 다량체성 e-셀렉틴 길항물질 | |
| KR20220012246A (ko) | E-셀렉틴, 갈렉틴-3, 및/또는 cxcr4 케모카인 수용체의 갈락토오스 연결된 다량체성 글리코모방체 억제제 | |
| EP3993870A1 (en) | Novel galactoside inhibitor of galectins | |
| WO2021086816A1 (en) | Galectin-3 inhibiting c-glycosides | |
| US20240270724A1 (en) | Galectin-3 inhibiting c-glycosides | |
| US20240287121A1 (en) | Galectin-3 inhibiting c-glycoside oximes | |
| JP2023508363A (ja) | ガレクチン-3阻害性c-グリコシドケトン、エーテル、およびアルコール |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D13-X000 | Search requested |
St.27 status event code: A-1-2-D10-D13-srh-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |